T-cell recovery and evidence of persistent immune activation 12 months after severe COVID-19

Patrick Taeschler1, Sarah Adamo1, Yun Deng1, Carlo Cervia1, Yves Zurbuchen1, Stéphane Chevrier2,3, Miro E. Raeber1, Sara Hasler1, Esther Bächli4, Alain Rudiger5, Melina Stüssi-Helbling6, Lars C. Huber6, Bernd Bodenmiller2,3, Onur Boyman1,7, Jakob Nilsson1

1Department of Immunology, University Hospital Zurich (USZ), Zurich, Switzerland
2Department of Quantitative Biomedicine, University of Zurich, Zurich, Switzerland
3Institute of Molecular Health Sciences, ETH Zurich, Zurich, Switzerland
4Clinic for Internal Medicine, Hirslanden Klinik St. Anna, Lucerne, Switzerland
5Department of Medicine, Limmattal Hospital, Schlieren, Switzerland
6Clinic for Internal Medicine, City Hospital Triemli Zurich, Zurich, Switzerland
7Faculty of Medicine, University of Zurich, Zurich, Switzerland

Abstract

Background: T-cell lymphopenia and functional impairment is a hallmark of severe acute coronavirus disease 2019 (COVID-19). How T-cell numbers and function evolve at later timepoints after clinical recovery remains poorly investigated.

Methods: We prospectively enrolled and longitudinally sampled 173 individuals with asymptomatic to critical COVID-19 and analyzed phenotypic and functional characteristics of T cells using flow cytometry, 40-parameter mass cytometry, targeted proteomics, and functional assays.

Results: The extensive T-cell lymphopenia observed particularly in patients with severe COVID-19 during acute infection had recovered 6 months after infection, which was accompanied by a normalization of functional T-cell responses to common viral antigens. We detected persisting CD4+ and CD8+ T-cell activation up to 12 months after infection, in patients with mild and severe COVID-19, as measured by increased HLA-DR and CD38 expression on these cells. Persistent T-cell activation after COVID-19 was independent of administration of a COVID-19 vaccine post-infection. Furthermore, we identified a subgroup of patients with severe COVID-19 that presented with persistently low CD8+ T-cell counts at follow-up and exhibited a distinct phenotype during acute infection consisting of a dysfunctional T-cell response and signs of excessive pro-inflammatory cytokine production.
Acute coronavirus disease 2019 (COVID-19), caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is associated with a broad clinical spectrum ranging from asymptomatic infection to severe disease with development of acute respiratory distress syndrome (ARDS)\textsuperscript{1–5}. Several studies have identified risk factors for the development of severe disease including advanced age, hypertension, diabetes mellitus, and obesity\textsuperscript{6–9}. Furthermore, the development of severe disease has been associated with a dysregulated innate immune response against SARS-CoV-2\textsuperscript{10}, including an inflammatory phenotype and a dysregulated T-cell response\textsuperscript{11,12}. The development of virus-specific T cells is a central part of antiviral immunity toward SARS-CoV-2, as virus-specific T cells rapidly eliminate infected cells through cell-mediated mechanisms and support B-cell-mediated production of virus-neutralizing antibodies\textsuperscript{8,13,14}. It has been convincingly shown that severe COVID-19 is associated with extensive T-cell lymphopenia, especially in the CD8\textsuperscript{+} T-cell compartment\textsuperscript{8,10,12,17,18}. The T-cell lymphopenia is linked to extensive T-cell apoptosis, activation and exhaustion as well as impaired T-cell function\textsuperscript{12}. However, it is unclear whether the T-cell perturbations observed in the acute phase persist, or whether the peripheral T-cell compartment recovers after acute infection. To investigate alterations of the immune system after acute COVID-19, we performed mass cytometry, flow cytometry, targeted proteomics, and functional assays at 6 and 12 months after SARS-CoV-2 infection in a cohort of 173 COVID-19 patients and 42 healthy controls.

**Conclusion:** Our study suggests that T-cell numbers and function recover in most patients after COVID-19. However, we find evidence of persistent T-cell activation up to 12 months after infection and describe a subgroup of severe COVID-19 patients with persistently low CD8\textsuperscript{+} T-cell counts exhibiting a dysregulated immune response during acute infection.

**KEYWORDS**
COVID-19, follow-up, recovery, SARS-CoV-2, T cells

**GRAPHICAL ABSTRACT**
In a multicentric cohort of 173 COVID-19 patients followed-up to 1 year we found evidence of functional and numeric T cell recovery. COVID-19 patients showed persistent moderate T cell activation at follow-up timepoints. A subgroup of severe COVID-19 patients exhibited low CD8\textsuperscript{+} T cell counts at follow-up, coupled to an inflammatory immune signature and T cell exhaustion.

Abbreviations: COVID-19, coronavirus disease 2019; SARS-CoV-2, severe acute respiratory syndrome coronavirus type 2

## 1 | INTRODUCTION

Acute coronavirus disease 2019 (COVID-19), caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is associated with a broad clinical spectrum ranging from asymptomatic infection to severe disease with development of acute respiratory distress syndrome (ARDS)\textsuperscript{1–5}. Several studies have identified risk factors for the development of severe disease including advanced age, hypertension, diabetes mellitus, and obesity\textsuperscript{6–9}. Furthermore, the development of severe disease has been associated with a dysregulated immune response against SARS-CoV-2\textsuperscript{8,10,12,17,18}, including an innate immune response with a persistent inflammatory phenotype and a dysregulated T-cell response\textsuperscript{11,12}. The development of virus-specific T cells is a central part of antiviral immunity toward SARS-CoV-2, as virus-specific T cells rapidly eliminate infected cells through cell-mediated mechanisms and support B-cell-mediated production of virus-neutralizing antibodies\textsuperscript{8,13,14}. It has been convincingly shown that severe COVID-19 is associated with delayed virus-specific T-cell response, which in turn is associated with increased and prolonged viral shedding\textsuperscript{15,16}. We and others have reported that severe COVID-19 is associated with extensive T-cell lymphopenia, especially in the CD8\textsuperscript{+} T-cell compartment\textsuperscript{8,10,12,17,18}. The T-cell lymphopenia is linked to extensive T-cell apoptosis, activation and exhaustion as well as impaired T-cell function\textsuperscript{12}. However, it is unclear whether the T-cell perturbations observed in the acute phase persist, or whether the peripheral T-cell compartment recovers after acute infection. To investigate alterations of the immune system after acute COVID-19, we performed mass cytometry, flow cytometry, targeted proteomics, and functional assays at 6 and 12 months after SARS-CoV-2 infection in a cohort of 173 COVID-19 patients and 42 healthy controls.

## 2 | RESULTS

### 2.1 | Study cohort characteristics

We conducted a prospective, observational and cross-sectional study on reverse transcriptase quantitative polymerase chain reaction (rt-qPCR)-positive COVID-19 patients (n = 173) recruited at four different centers in the Canton of Zurich, Switzerland (Figure S1). The patients...
were stratified into mild (n = 109) or severe (n = 64) disease based on maximal disease severity according to the world health organization (WHO) classification criteria. After sampling in acute disease, patients were followed up at 6 (n = 113) and 12 months (n = 90) after infection. 42 individuals with a negative history of SARS-CoV-2 infection and negative serological testing were also included in the study as healthy controls (Figure 1A). Clinical history and routine laboratory parameters including flow cytometry were obtained (Table 1). Comprehensive inflammation marker proteomics based on proximity extension assay technology (Olink®), and in-depth T-cell phenotypic analyses by mass cytometry were performed (Figure 1A). As described, advanced age and several comorbidities, including hypertension, diabetes mellitus, and heart disease, were associated with severe disease (Table 1). As SARS-CoV-2 vaccines became available, participants were vaccinated with a single- or double-dose regimen, mostly with the mRNA-based COVID-19 vaccines BNT162b2 (Pfizer/BioNTech) or mRNA-1273 (Moderna). At the 12-month follow-up, 63.3% of study participants had been vaccinated (Table 1). Five patients in our control group subsequently were infected with SARS-CoV-2, which allowed for a comparison of their data before infection, during acute infection, and at follow-up.

2.2 | T-cell recovery at 6 months after infection

As previously described, we observed marked peripheral lymphopenia in acute severe COVID-19, involving CD4+ and CD8+ T cells as well as NK cells (Figure 1B). At 6 months after infection, CD4+ T cell, CD8+ T cell, and NK cell counts in the peripheral blood had returned to normal levels in the majority of the patients, and remained stable between 6 and 12 months (Figure 1B). Analysis of five participants initially included in the control group, who were subsequently infected with SARS-CoV-2 (n = 3 mild, n = 2 severe), confirmed the transient nature of the lymphopenia in severe disease, with normalization of T-cell and NK cell counts (Figure 1C). Of note, the two individuals that eventually developed severe disease had peripheral CD8+ T-cell values in the low range prior to infection (Figure 1C).

In line with previous data, we observed a profound reduction in peripheral eosinophils and basophils in both mild and severe acute COVID-19, which normalized at 6 months after infection and remained stable thereafter (Figure 1D). An analogous pattern was observed in the subgroup of patients sampled before and after infection (Figure 1E).

As previously reported, we detected diminished functional responses against multiple viral antigens, including adenovirus, cytomegalovirus (CMV), herpes simplex virus (HSV) 1, HSV-2, and varicella zoster virus (VZV) during acute severe COVID-19 (Figure 1F). We previously hypothesized that this decreased T-cell reactivity was due to a reduction in precursor frequency associated with the observed lymphopenia. Thus, in line with our observation of normalized T-cell counts 6 months after infection, we observed restored functional T-cell responses to most of the tested viral antigens at 6 months (Figure 1G). Taken together, these findings indicate a normalization of T-cell counts and functional responses to common viral antigens by 6 months after acute SARS-CoV-2 infection.

2.3 | Evidence of persistent T-cell activation following SARS-CoV-2 infection

Enhanced T-cell activation with increased surface expression of CD38 and HLA-DR has been shown in acute COVID-19.

Consistently, we also found a markedly increased frequency of CD38+ HLA-DR+ T cells during acute infection as compared to healthy individuals, which was more pronounced in CD8+ compared to CD4+ cells. (Figure 2A,B). Although frequencies of activated T cells decreased consistently at follow-up, both CD38+ HLA-DR+ CD4+ and CD8+ T cells remained elevated in COVID-19 patients compared to healthy controls, even at 12 months after infection (Figure 2A,B). This increase was observed for patients with mild and severe disease, with no apparent reduction between the 6-month and 12-month follow-up (Figures 2A,B and S2A,B).

When examining the patients for which sampling before disease onset was available, we also observed elevated frequencies of CD38+ HLA-DR+ CD4+ T cells 6 months after severe COVID-19, whereas the patients with mild COVID-19 displayed a more diverse pattern (Figure 2C). In contrast, frequencies of CD38+ HLA-DR+ CD8+ T cells returned to pre-infection levels at 6-month follow-up in this subgroup (Figure 2D).

We next wondered whether a prolonged increase in T-cell activation would be associated with a persistent increase of serum pro-inflammatory markers. Indeed, the amounts of C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor α (TNF-α) all showed a positive correlation with the frequency of activated CD4+ and CD8+ T cells at 6 and 12 months after infection (Figure 2E,F).
However, this was not the case for interferon γ (IFN-γ), which did not correlate with the level of activated CD4+ or CD8+ T cells post-infection (Figure 2E,F). Collectively, our data showed evidence for low level, persisting T-cell activation, correlating with increased pro-inflammatory cytokine production up to 12 months after infection, affecting both mild and severe COVID-19 patients.
2.4 | Impact of COVID-19 vaccination on T-cell activation and inflammation markers

As SARS-CoV-2 vaccines became available during the follow-up phase of our study, some participants were vaccinated with a single- or double-dose regimen of the available mRNA-based COVID-19 vaccines. In our cohort, 10.6% and 63.3% had received an mRNA-based SARS-CoV-2 vaccine at the 6- and 12-month follow-up, respectively (Table 1). Since vaccination is accompanied by a transient inflammatory reaction, we explored the influence of vaccination on T-cell activation and pro-inflammatory cytokine levels. To this end, we grouped recovered COVID-19 patients by vaccination status into (i) unvaccinated at 6 months after infection, (ii) unvaccinated at 12 months after infection, (iii) vaccinated within 30 days of sample collection, and (iv) vaccinated more than 30 days before sample collection. Interestingly, all groups showed higher T-cell activation than healthy controls (Figure 3A). In CD4+ T cells, we observed no marked difference in T-cell activation between recently vaccinated participants and participants vaccinated more than 30 days prior to sampling (Figure 3A). Conversely, CD8+ T cells showed a markedly increased activation in individuals sampled early after vaccination, which was attenuated at the later time points (Figure 3A). Accordingly, starting 5 days after vaccination, we observed a decline of activated CD8+ T cells, which was less apparent for activated CD4+ T cells (Figure 3B). Regarding the effect of COVID-19 vaccination on inflammation markers, we did not observe consistent changes in vaccinated individuals, which was possibly due to the short duration and low level of systemic inflammation after COVID-19 vaccination (Figure 3C). However, a discrete negative association with time after vaccination was observed for TNF-α, but not for other inflammation markers (Figure 3D). Taken together, we found evidence of transient CD8+ T-cell activation following mRNA-based vaccination in recovered COVID-19 patients, whereas CD4+ T cells and systemic inflammatory markers remained largely unaffected.

2.5 | Persistently low CD8+ T cells in subgroup of severe COVID-19 patients

T-cell lymphopenia is a well-described feature of severe acute COVID-19 but whether it is elicited by acute SARS-CoV-2 infection or rather a pre-existing risk factor for severe COVID-19 remains unclear. In the whole cohort, recovery of peripheral CD4+ and CD8+ T-cell counts was observed already at the 6-month follow-up (Figure 4A). However, we identified a subgroup of patients (n = 10) with severe COVID-19 that presented with CD8+ T-cell counts <250/μl at 6-month follow-up, which was maintained at 12 months after infection (Figures 4A and S3A). This CD8-low subgroup exhibited markedly lower CD8+ T-cell counts during acute infection compared to other patients with severe disease (Figure 4A). To investigate the characteristics of the CD8-low subgroup during acute COVID-19, we used a multivariate analysis comprising 130 parameters, including routine laboratory parameters, a comprehensive inflammation proteomics panel and demographic parameters (Tables 2 and S1). This analysis allowed for a separation of severe COVID-19 patients and healthy individuals, while mild COVID-19 patients showed an intermediate phenotype (Figure 4B). Patients in the CD8-low subgroup trended toward more pronounced perturbations, which reflected marked differences in numerous parameters when compared to severe COVID-19 patients with CD8+ T-cell counts >250/μl (CD8-high) at 6 months after infection (Figures 4C and S3B). The patients in the CD8-low subgroup were almost exclusively male, in contrast to the more balanced sex distribution observed in the CD8-high subgroup or in patients with mild disease (Figure 4D). Furthermore, the patients in the CD8-low subgroup were older and presented with decreased peripheral NK cells and monocytes, as well as increased plasmablasts during acute COVID-19 (Figure 4E). This was accompanied by increased levels of several inflammation markers, including CRP, TNF-α, soluble IL-2Rα, and CXCL9 (Figure 4F). At 6 months after acute infection, we observed a normalization of inflammation markers and an increased monocyte count in the CD8-low subgroup (Figure 4G).

Collectively, our data provide evidence of a subgroup of patients with low CD8+ T-cell counts after recovery from severe COVID-19, encompassing elderly, predominantly male individuals exhibiting an accentuated pro-inflammatory immunological profile during acute infection. These features could possibly be linked to a pre-existing CD8+ T-cell lymphopenia that predisposes to the development of severe disease.

2.6 | Persistently low CD8+ T cells are associated with increased CD8+ T-cell exhaustion

Next, we investigated whether the reduced CD8+ T-cell counts in the CD8-low subgroup were accompanied by T-cell dysfunction during acute COVID-19. We took advantage of an extended CyTOF panel for T-cell phenotyping that was performed in a subgroup of included patients during acute disease and 6-month follow-up (n = 36 and n = 46, respectively). The CD8-low subgroup showed no differences during acute infection within the CD4+ T-cell compartment in terms of cell proliferation, activation, exhaustion, and apoptosis, as compared to other COVID-19 patients (Figure 5A). On the contrary, we observed elevated frequencies of proliferating, activated and exhausted cells within the CD8+ T-cell compartment of CD8-low patients during acute disease (Figure 5A). Correlation analyses with serum proteomics, flow cytometry data, and age in patients with mild or severe acute COVID-19 (n = 42) revealed an association of age and various pro-inflammatory markers with CD8+ T-cell activation, exhaustion, and apoptosis (Figure 5B). Conversely, age and pro-inflammatory markers negatively correlated with naive CD8+ T cells (Figure 5B). Furthermore, CD3+ and CD8+ T-cell counts correlated negatively with exhausted CD8+ and CD4+ T cells (Figure 5B).

The phenotypic changes of CD8+ T cells observed in the CD8-low subgroup were no longer significant at the 6-month follow-up apart from persistently elevated levels of exhausted CD8+ T cells (Figure 5C). Interestingly, we also detected increased frequencies of regulatory T cells and exhausted CD4+ T cells in the CD8-low
| TABLE 1 COVID-19 study cohort characteristics |
|---------------------------------------------|
| **Disease severity** | **Healthy controls** | **Acute COVID-19** | **6-month follow-up** | **12-month follow-up** |
| | | Mild | Severe | Mild | Severe | Mild | Severe |
| n | 42 | 109 (62.6%) | 64 (36.7%) | 76 (67.2%) | 37 (32.7%) | 64 (71.1%) | 26 (28.9%) |
| Demographics | | | | | | | |
| Age | 32 (28-52) | 34 (28-52) (ns) | 67 (57-78) (****) | 36 (29-53) (ns) | 64 (57-73) (****) | 35 (28-49) (ns) | 65 (53-72) (****) |
| Days PSO | - | 10 (7-16) | 13 (9-25) | 194 (185-203) | 210 (194-224) | 375 (367-387) | 386 (368-397) |
| Sex (female) | 24 (57.1%) | 54 (49.5%) | 27 (42.8%) | 39 (51.3%) | 14 (21.9%) | 64 (57-73) (****) | 8 (30.8%) |
| Covid vaccination | | | | | | | |
| Total | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| One shot | 0 (0%) | 0 (0%) | 0 (0%) | 5 (55.5%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Biontech/Pfizer | 0 (0%) | 0 (0%) | 0 (0%) | 6 (66.7%) | 1 (33.3%) | 0 (0%) | 0 (0%) |
| Moderna | 0 (0%) | 0 (0%) | 0 (0%) | 3 (33.3%) | 2 (66.7%) | 0 (0%) | 0 (0%) |
| Unknown/other | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Laboratory parameters | | | | | | | |
| Lymphocytes (G/L) | 1.8 (1.48-2.33) | 1.81 (1.31-2.17) (ns) | 0.71 (0.55-1.09) (****) | 1.95 (1.66-2.41) (ns) | 1.76 (1.48-2.26) (ns) | 2.3 (1.82-2.69) (ns) | 1.67 (1.43-2.19) (ns) |
| CRP (mg/L) | 0.6 (0.4-1.6) | 1.3 (0.1-4.9) (**) | 58 (31-117) (****) | 0.6 (0.6-1.3) (ns) | 2.2 (1.7-5.1) (**) | 1 (0.6-2.2) (**) | 1.6 (1-3.3) (**) |
| TNF-α (ng/L) | 8.1 (6.38-10.0) | 9.8 (7.6-12.0) (* | 16.5 (13.8-20.6) (****) | 9.05 (6.88-10.90) (ns) | 11.6 (9.3-14.6) (****) | 8.55 (6.92-10.8) (ns) | 9.9 (8.7-13.6) (****) |
| IL-6 (ng/L) | 0.45 (0-1.12) | 1.3 (0.1-4.9) (**) | 20.3 (7.6-57.3) (****) | 0.9 (0-2.1) (ns) | 1.7 (0.2-5.4) (**) | 1.25 (0.4-2.4) (**) | 1.7 (0.2-3.1) (**) |
| Anti-S1 IgA (OD ratio) | 0.33 (0.25-0.46) | 1.77 (0.7-4.8) (****) | 6.34 (2.4-10.0) (****) | 2.5 (1.6-5.0) (****) | 5.1 (3.1-7.4) (****) | 8.4 (3.0-10.0) (****) | 7.4 (4.2-8.4) (****) |
| Anti-S1 IgG (OD ratio) | 0.2 (0.17-0.25) | 0.61 (0.3-2.2) (****) | 4.6 (0.3-9.3) (****) | 2.7 (1.3-5.7) (****) | 7.3 (5.2-8.6) (****) | 10.0 (4.0-10.0) (****) | 9.2 (7.1-11.3) (****) |
| Comorbidities: | | | | | | | |
| Hypertension | 5 (11.9%) | 13 (11.9%) (ns) | 36 (57.8%) (****) | 7 (9.2%) (ns) | 20 (34.1%) (****) | 6 (9.4%) (ns) | 14 (53.8%) (****) |
| Diabetes | 2 (4.7%) | 6 (5.5%) (ns) | 19 (29.7%) (ns) | 4 (5.3%) | 12 (32.4%) (****) | 4 (6.3%) | 6 (23.1%) (ns) |
| Heart disease | 1 (2.4%) | 6 (5.5%) (ns) | 24 (37.5%) (****) | 2 (2.6%) | 15 (40.5%) (****) | 2 (3.1%) | 9 (34.6%) (ns) |
| Lung disease | 6 (14.2%) | 10 (9.2%) (ns) | 12 (18.8%) (ns) | 5 (6.5%) | 11 (29.7%) (ns) | 5 (7.8%) | 9 (34.6%) (ns) |
| Malignancy | 1 (2.4%) | 3 (2.8%) (ns) | 7 (10.9%) (****) | 3 (3.9%) | 4 (10.8%) (ns) | 0 (0%) | 5 (19.2%) (ns) |
| Kidney disease | 0 (0%) | 8 (7.3%) (ns) | 16 (25.0%) (ns) | 3 (3.9%) | 9 (24.3%) (ns) | 3 (4.7%) | 8 (30.7%) (ns) |

Note: For continuous variables, medians and interquartile ranges (in parentheses) are shown, with p-values obtained by Mann–Whitney U-test, compared to healthy individuals. For categorical variables, numbers of individuals and percentage of corresponding subgroup (in parentheses) are shown, with p-values calculated by Fisher’s exact test compared to healthy individuals. ns, non-significant; *, p < .05; **, p < .01; ***, p < .001; ****, p < .0001. PSO, post symptom onset; OD, optical density; S1, SARS-CoV-2 spike subunit S1.
subgroup 6 months after acute infection (Figure 5C). In summary, we found evidence of a dysfunctional CD8+ T-cell response in the CD8-low subgroup during severe acute COVID-19. Furthermore, older age, low naive CD8+ T cells and increased CD8+ T-cell activation, exhaustion and apoptosis were linked to signs of extensively elevated systemic inflammation during acute COVID-19.

FIGURE 2 Persistent T-cell activation 12 months after acute COVID-19. (A–D) Frequency of activated (CD38+HLA-DR+) CD4+ (A, C) and CD8+ (B, D) T cells in the whole study cohort (healthy, n = 41; acute, n = 167; 6 months, n = 111; 12 months, n = 90) (A, B), or in individuals that were sampled prior to SARS-CoV-2 infection (C, D; n = 5). p-values in (A and B) were obtained by Mann–Whitney U-tests and adjusted for multiple comparisons by the Holmes method. p-values without brackets indicate comparison to healthy controls. Horizontal lines in violin plots indicate medians. (E, F) Correlation of activated (CD38+HLA-DR+) CD4+ (E) and CD8+ T (F) cells with inflammation markers, that is, CRP (n = 151), IL-6 (n = 201), TNF-α (n = 201), and IFN-γ (n = 201), at 6-month or 12-month follow-up. Regression lines represent simple linear regression models, with Pearson's correlation coefficient calculated for all observations.
Figure 3 Immune activation following mRNA-based COVID-19 vaccination. (A) Frequency of activated (CD38\(^+\)HLA-DR\(^+\)) CD4\(^+\) and CD8\(^+\) T cells in healthy controls (n = 41) and followed up COVID-19 patients grouped according to their vaccination status, that is, unvaccinated (6 months, n = 100; 12 months, n = 33) or vaccinated (≤30d before sampling, n = 21; >30d before sampling, n = 47). (B) Temporal association of activated CD4\(^+\) and CD8\(^+\) T cells following vaccination, in followed up COVID-19 patients that were vaccinated within 30 days prior to sampling (n = 21). Regression lines represent simple linear regression models, starting from 5 days after the last vaccine shot, with Pearson’s correlation coefficient calculated for all observations. (C) Inflammation markers, that is, CRP (n = 188), IL-6 (n = 243), TNF-\(\alpha\) (n = 243), and IFN-\(\gamma\) (n = 243), in healthy controls or followed up COVID-19 patients grouped according to their vaccination status and sampling timepoint. (D) Temporal trajectories of inflammation markers following mRNA vaccination in followed up COVID-19 patients that were vaccinated within 30 days prior to sampling (n = 21). Regression lines represent simple linear regression models, with Pearson’s correlation coefficient calculated for all observations. Horizontal bars in violin plots represent medians. ns, non-significant; *, p < .05; **, p < .01; ***, p < .001; ****, p < .0001
Figure 4: Persistent peripheral CD8+ T-cell lymphopenia in a subgroup recovering from severe COVID-19. (A) Temporal trajectories of peripheral CD4+ and CD8+ T-cell counts in COVID-19 patients during acute infection (n = 167), and at 6-month (n = 111) and 12-month (n = 36) follow-up, separating patients with mild vs. severe COVID-19. Regression lines indicate separate simple linear regression models, with Pearson’s correlation coefficient R. The CD8− low subgroup (n = 10) was defined as patients with severe disease that presented with CD8+ counts below 250/μl at the 6-month follow-up. (B) Principal component analysis (PCA) including 131 parameters during acute COVID-19 (Table S1). Each dot represents an individual study participant, including healthy controls (n = 27) and acute COVID-19 patients (n = 127). (C) Loadings of PCA depicted in (B), with each parameter shown as an individual dot. Colors indicate group of participants with higher mean for each parameter. Dot sizes indicate p-values of the difference, as calculated by Mann–Whitney U-test (Table S1 and Figure S3B). (D) Sex distribution in healthy individuals (n = 42), and mild (n = 109) and severe (n = 36) COVID-19 patients, dividing severe COVID-19 patients into subgroups based on CD8+ T-cell counts at 6-month follow-up. (E, F) Selected parameters, of PCA in (B, C), comparing severe acute COVID-19 patients of CD8−high and CD8−low subgroups. (G) Selected inflammation markers and peripheral leukocyte counts in healthy controls and COVID-19 patients at 6-month follow-up, comparing severe COVID-19 patients of CD8−high (n = 26) and CD8−low (n = 10) subgroups. p-values in (E–G) were calculated using Mann–Whitney U-test. Horizontal lines in violin plots indicate medians. ns, non-significant; *, p < .05; **, p < .01; ***, p < .001; ****, p < .0001
TABLE 2  Patient characteristics of CD8-high and CD8-low severe acute COVID-19 patients

| Subgroup                      | Severe acute COVID-19 |   |
|-------------------------------|------------------------|---|
|                               | CD8-high               | CD8-low |
| CD8⁺ count at 6-month follow-up| >250/μl               | <250/μl |
| n                             | 26 (72.2%)             | 10 (27.8%) |
| Demographics                  |                        |   |
| Age                           | 60 (50-65)             | 75 (68-80) |
| Days PSO                      | 16 (9-35)              | 13 (10-21) |
| Sex (female)                  | 12 (46.2%)             | 1 (10.0%) |
| Laboratory parameters         |                        |   |
| Lymphocytes (G/L)             | 0.9 (0.6-1.4)          | 0.4 (0.3-0.5) |
| CRP (mg/L)                    | 41 (16-104)            | 101 (63-191) |
| TNFalpha (ng/L)               | 14.5 (10.8-17.2)       | 21.5 (17.8-23.7) |
| IL-6 (ng/L)                   | 17.9 (7.4-52.4)        | 44.6 (15.6-102) |
| Anti-S1 IgA (OD ratio)        | 5.7 (1.6-9.9)          | 9.2 (3.3-10.9) |
| Anti-S1 IgG (OD ratio)        | 2.6 (0.4-10.2)         | 5.1 (0.4-8.6) |
| Comorbidities                 |                        |   |
| Hypertension                  | 12 (46.1%)             | 8 (80.0%) |
| Diabetes                      | 9 (25.0%)              | 3 (30.0%) |
| Heart disease                 | 6 (23.1%)              | 8 (80.0%) |
| Lung disease                  | 6 (23.1%)              | 3 (30.0%) |
| Malignancy                    | 1 (3.8%)               | 0 (0%) |
| Kidney disease                | 4 (15.3%)              | 4 (40.0%) |

Note: For continuous variables, medians and interquartile ranges (in parentheses) are shown, with p-values obtained by Mann-Whitney U-test. For categorical variables, numbers of individuals and percentage of corresponding subgroup (in parentheses) are shown, with p-values obtained by Fisher’s exact test. OD, optical density; S1, SARS-CoV-2 spike subunit S1.

3 | DISCUSSION

Acute COVID-19 has been associated with peripheral T-cell lymphopenia, and the extent of lymphopenia strongly correlated with disease severity⁹,¹⁰,¹²,¹⁷. We and others have shown evidence of increased T-cell apoptosis, especially affecting CD8⁺ T cells in severe acute COVID-19¹²,¹⁷. However, it has been unclear whether these immune disruptions persist after recovery from acute COVID-19. In the current study, we present the follow-up of a large COVID-19 cohort over a period of up to 12 months to further decipher the phenotypic and functional alterations in T cells. By using high-dimensional mass cytometry, functional assays, and routine laboratory testing, we conclusively show (i) a functional and numeric recovery of peripheral leukocyte compartments 6 months after acute COVID-19, (ii) the persistence of moderate T-cell activation for up to 1 year after SARS-CoV-2 infection, and (iii) persistently low CD8⁺ T-cell counts in a subgroup of patients at follow-up, coupled to excessive inflammation during acute COVID-19, suggesting that pre-existing CD8⁺ T-cell lymphopenia could be a risk factor for severe COVID-19. These results argue against a persistent damage to the T-cell compartment and memory T-cell responses upon COVID-19 infection, in contrast to what has been shown for measles virus infection, where a broad depletion of memory cells is observed, leading to loss of previously acquired adaptive immunity²⁷,²⁸ and increased susceptibility to subsequent infections²⁹. In contrast, the correlation of T-cell lymphopenia with severe disease and the transient nature of the observed T-cell depletion are in line with previous studies on the related human coronaviruses severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome-related coronavirus (MERS-CoV)³⁰,³¹. Although we observed a normalization of peripheral immune cell counts 6 months after acute infection, a slight but consistent increase in activated CD4⁺ and CD8⁺ T cells was evident in both patients with mild and severe COVID-19 at 6- and 12-month follow-up. T-cell activation was positively associated with persistently increased levels of several pro-inflammatory markers, including CRP, IL-6, and TNF-α. Since a substantial part of our patient cohort received an mRNA-based COVID-19 vaccine during the follow-up period, we investigated whether persisting T-cell activation was associated with vaccination. Our assay was sensitive enough to detect transient activation of peripheral CD8⁺ T cells following vaccination. However, the immune-stimulating effect of vaccination could not explain the immune activation observed in recovered COVID-19 patients, as immune activation was similar in vaccinated and non-vaccinated individuals. Thus, the cause of the increased immune activation observed in our study remains unclear, but it could be associated with residual tissue damage or persisting SARS-CoV-2 antigen, resulting in ongoing T- and B-cell immune responses³²,³³. Ongoing immune activation detected up to 12 months after mild and severe COVID-19 could potentially be related to long-term post-viral symptoms³⁴,³⁵, termed post-acute COVID-19 syndrome or long-COVID³⁶,³⁷, our study did, however, not investigate this aspect. Moreover, potential demographic confounders, such as age and general health status, could account for differences between patient groups and healthy controls. Further studies are needed to determine whether there is a...
The reduction pre-dated the SARS-CoV-2 infection, a proportionally reduced CD8 naive T-cell repertoire could partially account for a delay in building an efficient virus-specific T-cell response. Persistent CD8 T-cell lymphopenia was strongly associated with male sex, advanced age, increased inflammation, and CD8 T-cell exhaustion during acute COVID-19. Increased levels of exhausted CD8 T cells have been previously associated with an aging immune system. We only included very few patients with samples available prior to SARS-CoV-2 infection, precluding definitive conclusions. However, the two patients that subsequently developed severe disease in this subgroup both had peripheral CD8 T-cell counts in the low range before COVID-19. Thus, our data suggest that, at least in a subgroup of patients, a pre-existing deficiency in CD8 T-cell immunity could be associated with the development of an inflammatory phenotype and with severe COVID-19. Alternatively, it is conceivable that the apoptosis observed in severe COVID-19 could lead to persistently low CD8 T-cell counts in the peripheral blood of a subgroup of patients, although we did not observe an increased frequency of apoptotic cells in this specific subgroup. Further studies are needed to investigate how decreased CD8 T-cell counts are related to the breadth of the T-cell receptor repertoire in CD8-low individuals, and how this affects the development and quality of SARS-CoV-2-specific T- and B-cell immunity.

Our study has several limitations related to the observational study design, loss to follow-up, as well as the heterogeneity of the population.
study population, including COVID-19 disease course, drug treatment, and comorbidities. In summary, our study presents novel insights into the dynamics of T-cell perturbations following SARS-CoV-2 infection, including evidence of T-cell recovery at 6 months after infection in the majority of patients, persisting immune activation as well as the identification of a CD8 low subgroup with a distinct severe disease phenotype.

4 | METHODS

4.1 | Cohort recruitment

Following written informed consent, adult individuals were recruited for blood sampling between April 2020 and May 2021. All experiments conducted in this study were approved by the authorities of the Canton of Zurich, Switzerland (BASEC #2016-01440). 173 patients with RT-qPCR-confirmed SARS-CoV-2 infection were recruited during acute COVID-19 at four different hospitals in the Canton of Zurich, that is, University hospital Zurich (n = 110), City Hospital Triemli (n = 34), Limmattal Hospital (n = 15), and Uster Hospital (n = 14) between March 2020 and March 2021. Follow-up visits were conducted at 6 months (n = 113) and 12 months (n = 90) after recovery (Figure S1). Clinical history was obtained, and blood samples were collected at each sampling time point. Maximum disease severity was classified according to the world health organization (WHO) criteria into mild COVID-19, including asymptomatic (n = 4), mild illness (n = 93) and mild pneumonia (n = 12), and severe COVID-19, including severe pneumonia (n = 29) and ARDS (n = 35) (Table 1). According to the CD8+ T-cell count, severe COVID-19 patients were further divided at 6-month follow-up into a CD8-low (<250/µl, n = 10) and a CD8-high (>250/µl, n = 26) subgroup (Table 2). 42 participants with negative serology and history for SARS-CoV-2 were included as healthy controls. Five healthy controls were infected with SARS-CoV-2 after recruitment and subsequently included in the COVID-19 patient cohort.

4.2 | Immunoassays

Serum was collected with BD Vacutainer CAT serum tubes (Becton Dickinson). Immunoglobulin subsets, semi-quantitative anti-SARS-CoV-2 Spike S1 IgG and IgA and cytokines, including interleukin (IL) 1β, IL-2, IL-5, IL-6, IL-8, IL-10, IL-12, interferon (IFN) γ, tumor necrosis factor (TNF) α, and soluble IL-2 receptor (sIL-2 R) α were measured in accredited laboratories at the University Hospital Zurich, as previously described.

4.3 | Flow cytometry

Quantification of the main lymphocyte subsets was obtained by accredited laboratories at University Hospital Zurich, as previously established. A more comprehensive description of reagents and methodology is available in Table S2.

4.4 | Flow cytometric assay for specific cell-mediated immune responses in whole blood (FASCIA)

Clinically validated functional T-cell response assays were conducted as described previously. Briefly, whole blood cells were stimulated with mitogens/superantigens (pokeweed mitogen, Concanavalin A, Staphylococcus enterotoxin A), or viral antigens (adenovirus, VZV, HSV-1, HSV-2, or CMV) for 7 days. As a read-out, the difference of CD3+ blast frequency compared to unstimulated samples was assessed by flow cytometry.

4.5 | Serum proteomics

Serum samples were analyzed by commercially available proximity extension assay-based technology (Olink® Proteomics) in a 92-marker inflammation panel, as previously described. All reported samples passed the quality control, and six markers were excluded because more than half of samples did not exceed the detection limit.

4.6 | Mass cytometry

40-parametric mass cytometric analysis was performed using the same antibody panel (Table S3) and methodology as previously described for this cohort. A comprehensive description of the computational pipeline used for data pre-processing is available in Crowell et al.

4.7 | Statistics

All statistical analyses were performed using R (version 4.1.0) and RStudio (1.4.1717). Unless specified differently, between group comparison was performed using unpaired, non-parametric testing (Mann–Whitney U). As indicated, p-values were adjusted for multiple comparisons using the Holm method for tests shown in the same plot. Principal component analyses (PCA) were performed with scaled, centered variables, and variable coordinates were used to illustrate loadings. Correlations of numeric variables are shown as simple linear regression models and quantified with Spearman’s or Pearson’s rank correlation as annotated. For statistical analysis and illustration, various packages were used, including stats (4.2.0), factoextra (1.0.7), ggplot2 (3.3.5), ggfortify (0.4.12), and corrplot (0.90).

AUTHOR CONTRIBUTIONS

PT and SA contributed to study design, patient recruitment, data collection, data analysis, and data interpretation. YD contributed to data analysis and interpretation. CC and YZ contributed to study design, patient recruitment, and data collection. SC and BB contributed to the CyTOF data collection and analysis. MER, SH, EB, AR, MS-H, and LCH contributed to patient recruitment and clinical management. JN wrote the manuscript, with contributions from PT, SA, and
OB. JN, OB, and BB contributed to study conception and design, data analysis, and data interpretation. All authors reviewed and approved the final version of the manuscript.

ACKNOWLEDGEMENTS
We thank Andrea Kalberer, Alessandra Guaita, Claudia Meloni, Jennifer Jörgen, Jana Epprecht, Claudia Bachmann, the members of the transplantation immunology laboratory, and the Boyman laboratory for their support and the helpful discussions. We also thank Andrea Jacobs and Sujana Sivapatham of the Bodenmiller laboratory who performed the CyTOF experiments. The study overview graphic was generated with BioRender.com. Open access funding provided by Universität Zurich.

CONFLICT OF INTEREST
Dr. Nilsson reports grants from Swiss National and an Innovation grant of University Hospital Zurich, during the conduct of the study. Dr. Bodenmiller reports grants from Clinical Research Priority Program of University of Zurich, Boyman reports grants from Swiss National Science Foundation, during the conduct of the study. Dr. Bodenmiller reports a Young Talents in Clinical Research Project Grant by the Swiss Academy of Medical Sciences and the G. & J. Bangerter-Rhyner Foundation, during the conduct of the study. Dr. Raeber reports grants from Swiss National Science Foundation, grants from Pandemic Fund of the University of Zurich, during the conduct of the study. Dr. Bodenmiller reports grants from Swiss National Science Foundation, grants from Pandemic Fund of the University of Zurich, during the conduct of the study. Dr. Boyman reports grants from Swiss National Science Foundation, grants from Clinical Research Priority Program of University of Zurich, and an Innovation grant of University Hospital Zurich, during the conduct of the study. Dr. Nilsson reports grants from Swiss National Science Foundation, during the conduct of the study.

ORCID
Patrick Taeschler https://orcid.org/0000-0003-0522-7629
Sarah Adamo https://orcid.org/0000-0002-6161-3156
Yun Deng https://orcid.org/0000-0002-8204-9021
Carlo Cervia https://orcid.org/0000-0001-7120-8739
Yves Zurbuchen https://orcid.org/0000-0001-5387-9950
Stéphane Chevrier https://orcid.org/0000-0002-9216-7910
Miro E. Raebler https://orcid.org/0000-0003-2609-0246
Sara Hasler https://orcid.org/0000-0001-7357-9090
Esther Bächli https://orcid.org/0000-0003-4887-7576
Alain Rudiger https://orcid.org/0000-0001-7943-7624
Melina Stüssi-Helbling https://orcid.org/0000-0002-7896-6644
Lars C. Huber https://orcid.org/0000-0001-5378-4716
Bernd Bodenmiller https://orcid.org/0000-0002-6325-7861
Onur Boyman https://orcid.org/0000-0001-8279-5545
Jakob Nilsson https://orcid.org/0000-0001-5091-8133

REFERENCES
1. Arons MM, Hatfield KM, Reddy SC, et al. Presymptomatic SARS-CoV-2 infections and transmission in a skilled nursing facility. N Eng J Med. 2020;382(22):2081-2090.
2. Tong Z-D, Tang A, Li K-F, et al. Potential presymptomatic transmission of SARS-CoV-2, Zhejiang province, China. 2020. Emerg Infect Dis. 2020;26(5):1052-1054.
3. Li R, Pei S, Chen B, et al. Substantial undetected infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2). Science. 2020;368(6490):489-493.
4. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese center for disease control and prevention. JAMA. 2020;323(12):1239-1242.
5. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020;8(5):475-481.
6. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-1062.
7. Gao Y, Ding M, Dong X, et al. Risk factors for severe and critically ill COVID-19 patients: a review. Allergy. 2021;76(2):428-455.
8. Cervia C, Nilsson J, Zurbuchen Y, et al. Systemic and mucosal antibody responses specific to SARS-CoV-2 during mild versus severe COVID-19. J Allergy Clin Immunol. 2021;147(2):S545-S557.e549, 557.e9.
9. Du R-H, Liang L-R, Yang C-Q, et al. Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study. Eur Respir J. 2020;55(5):2000524.
10. Hadjadj J, Yatim N, Barnabei L, et al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science. 2020;369(6504):718-724.
11. Chevrier S, Zurbuchen Y, Cervia C, et al. A distinct innate immune signature marks progression from mild to severe COVID-19. Cell Rep Med. 2021;2(1):100166.
12. Adamo S, Chevrier S, Cervia C, et al. Profound dysregulation of T cell homeostasis and function in patients with severe COVID-19. Allergy. 2021;76:2866-2881.
13. Adamo S, Michler J, Zurbuchen Y, et al. Signature of long-lived memory CD8+ T cells in acute SARS-CoV-2 infection. Nature. 2021;602:148-155.
14. Israelow B, Mao T, Klein J, et al. Adaptive immune determinants of viral clearance and protection in mouse models of SARS-CoV-2. Sci Immunol. 2021;6(64):eab4509.
15. Moderbacher CR, Ramirez SI, Dan JM, et al. Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity. Cell. 2020;183(4):996-1012.e1019, 1012.e19.
16. Liu Y, Yan L-M, Wan L, et al. Viral dynamics in mild and severe cases of COVID-19. Lancet Infect Dis. 2020;20(6):656-657.
17. Diao B, Wang C, Tan Y, et al. Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19). Front Immunol. 2020;11:827.
18. Feng Y, Ling Y, Bai T, et al. COVID-19 with different severities: a multicenter study of clinical features. Am J Respir Crit Care Med. 2020;201(11):1380-1388.
19. WHO. Living guidance for clinical management of COVID-19. 2020; World health organization (WHO). https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-2. Accessed January 16, 2022.
20. Rodrigue L, Pekkarinen PT, Lakshmikanth T, et al. Systems-level immunomonitoring from acute to recovery phase of severe COVID-19. Cell Rep Med. 2020;1(5):100078.
21. Zhang J-J, Dong X, Cao Y-Y, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy. 2020;75(7):1730-1741.
22. Kuri-Cervantes L, Pampena MB, Meng W, et al. Comprehensive mapping of immune perturbations associated with severe COVID-19. Sci Immunol. 2020;5(49):eabd7114.
23. Mathew D, Giles JR, Baxter AE, et al. Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications. Science. 2020;369(6508):eabc8511.
24. Song JW, Zhang C, Fan X, et al. Immunological and inflammatory profiles in mild and severe cases of COVID-19. Nat Commun. 2020;11(1):1-10. 3410.
25. Kratzer B, Trapin D, Ettel P, et al. Immunological imprint of COVID-19 on human peripheral blood leukocyte populations. Allergy. 2021;76(3):751-765. doi:10.1111/all.1464726
26. Miller JD, van der Most RG, Akondy RS, et al. Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines. Immunity. 2008;28(5):710-722.
27. Mina MJ, Kula T, Leng Y, et al. Measles virus infection diminishes preexisting antibodies that offer protection from other pathogens. Science. 2019;366(6465):599-606.
28. Petrova VN, Sawatsky B, Han AX, et al. Incomplete genetic reconstitution of B cell pools contributes to prolonged immunosuppression after measles. Sci Immunol. 2019;4(41):eaaay6125.
29. Min C-K, Cheon S, Ha N-Y, et al. Comparative and kinetic analysis of viral shedding and immunological responses in MERS patients representing a broad spectrum of disease severity. Sci Rep. 2016;6(1):1-12.
30. Gaebler C, Wang Z, Lorenzi JC, et al. Evolution of antibody immunity to SARS-CoV-2. Nature. 2021;591(7851):639-644.
31. Moriyama S, Adachi Y, Sato T, et al. Temporal maturation of neutralizing antibodies in COVID-19 convalescent individuals improves potency and breadth to circulating SARS-CoV-2 variants. Immunity. 2021;54(8):1841-1852.e1844.
32. Davis HE, Assaf GS, McCorkell L, et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. Available at SSRN 3820561.
33. Huang C, Huang L, Wang Y, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021;397(10270):220-232.
34. Karlsson AC, Humbert M, Buggert M. The known unknowns of T cell immunity to COVID-19. Sci Immunol. 2020;5(53):eabc8511.
35. Bergamaschi L, Mescia F, Turner L, et al. Longitudinal analysis reveals that delayed bystander CD8+ T cell activation and early immune pathology distinguish severe COVID-19 from mild disease. Immunity. 2021;54(6):1257-1275, e1258, 1275.e8.
36. Zheng M, Karki R, Williams EP, et al. TLR2 senses the SARS-CoV-2 envelope protein to produce inflammatory cytokines. Nat Immunol. 2021;1:10-829-838.
37. Nilsson J, Granrot I, Mattsson J, Omazic B, Uhlin M, Thunberg S. Functionality testing of stem cell grafts to predict infectious complications after allogeneic hematopoietic stem cell transplantation. Vox Sang. 2017;112(5):459-468.
38. Crowell HL, Chevrier S, Jacobs A, et al. An R-based reproducible and user-friendly preprocessing pipeline for CyTOF data. F1000Research. 2020;9:1263.

SUPPORTING INFORMATION
Additional supporting information may be found in the online version of the article at the publisher’s website.

How to cite this article: Taeschler P, Adamo S, Deng Y, et al. T-cell recovery and evidence of persistent immune activation 12 months after severe COVID-19. Allergy. 2022;77:2468-2481. doi: 10.1111/all.15372